3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Leukemia, Myeloid, Acute
66
Myelodysplastic Syndromes
38
Leukemia, Myelomonocytic, Chronic
26
Leukemia
14
Myeloproliferative Disorders
10
Recurrence
7
Lymphoma
7
Hematologic Neoplasms
7
Neoplasms
6
Primary Myelofibrosis
5
Multiple Myeloma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasm, Residual
3
Myelodysplastic-Myeloproliferative Diseases
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Glioblastoma
2
Carcinoma, Renal Cell
2
Anemia, Refractory, with Excess of Blasts
2
Interventions
pembrolizumab
24
Radiotherapy
21
Cisplatin
21
Cetuximab
13
Carboplatin
11
Paclitaxel
8
Nivolumab
8
durvalumab
7
Radiotherapy, Intensity-Modulated
6
Docetaxel
6
Fluorouracil
5
Cyclophosphamide
5
zalutumumab
4
Everolimus
4
Amifostine
4
spartalizumab
3
fludarabine
3
epacadostat
3
cemiplimab
3
Ipilimumab
3
Immune Checkpoint Inhibitors
3
Gefitinib
3
Filgrastim
3
Erlotinib Hydrochloride
3
Celecoxib
3
Capecitabine
3
selpercatinib
2
palbociclib
2
fludarabine phosphate
2
bintrafusp alfa protein, human
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Head and Neck Neoplasms
×
Azacitidine
×
Clear all
NCT04729543
2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2
Recruiting
20 enrolled